HMGA2 (high mobility group AT-hook 2)

Show simple item record

dc.contributor.author Wei, Jian-Jun -
dc.date.accessioned 2018-03-13T11:38:35Z
dc.date.available 2018-03-13T11:38:35Z
dc.date.issued 2016 -
dc.identifier.citation Jian-Jun, Wei. HMGA2 (high mobility group AT-hook 2). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2016, 7, p. 403-412 -
dc.identifier.issn 1768-3262 -
dc.identifier.uri http://hdl.handle.net/2042/66056
dc.description.abstract HMGA2, the High Mobility Group A2 gene, is a non-histone and architectural transcription factor. As an oncofetal protein, HMGA2 plays an important role in development and contributes to the tumorigenesis of many epithelial and mesenchymal tumors. Upregulation of HMGA2 by non-random chromosomal translocations is common in mesenchymal tumors, whereas by the altered transcription regulation is likely the major mechanism in malignant epithelial tumors and it involves much more complex mechanisms. HMGA2 directly and indirectly regulates the multiple biological and oncogenic pathways. Its oncogenic property remains to be fully characterized. en
dc.language.iso en -
dc.publisher ARMGHM - Atlas Génétique des Cancers -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; http://AtlasGeneticsOncology.org/Genes/HMGICID82.html -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology en
dc.rights Open access resource - terms and conditions : http://irevues.inist.fr/utilisation -
dc.subject HMGA2 en
dc.subject Development en
dc.subject miRNA regulation en
dc.subject Stem cell self-renewal en
dc.subject transcription regulation en
dc.subject Oncofetal protein en
dc.subject neoplasia en
dc.subject Aging and senescence en
dc.subject epithelial-to-mesenchymal transition (EMT) en
dc.subject non-random chromosomal translocation. en
dc.subject.classification Genes Section en
dc.subject.mesh Breast Neoplasms/*pathology en
dc.subject.mesh Female en
dc.subject.mesh HMGA2 Protein/*physiology en
dc.subject.mesh Humans en
dc.subject.mesh MCF-7 Cells en
dc.subject.mesh Neoplasm Metastasis/*physiopathology en
dc.subject.mesh Phenotype en
dc.subject.mesh Receptor, PAR-1/*physiology en
dc.subject.mesh Vimentin/metabolism en
dc.subject.mesh Animals en
dc.subject.mesh Cell Transformation, Neoplastic/genetics/metabolism en
dc.subject.mesh Cystadenocarcinoma, Serous/*genetics/metabolism/*pathology en
dc.subject.mesh Epigenesis, Genetic en
dc.subject.mesh Female en
dc.subject.mesh Gene Expression Regulation, Neoplastic en
dc.subject.mesh HMGA2 Protein/genetics/metabolism en
dc.subject.mesh Humans en
dc.subject.mesh Neoplasm Grading en
dc.subject.mesh Ovarian Neoplasms/*genetics/metabolism/*pathology en
dc.subject.mesh BRCA1 Protein/genetics en
dc.subject.mesh Cell Line, Transformed en
dc.title HMGA2 (high mobility group AT-hook 2) en
dc.type Article -
dc.contributor.affiliation Floyd Elroy Patterson Research Professor of Pathology, Department of Pathology and Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Women's Health Research Institute, 251 East Huron Street, Feinberg 7-334, Chicago, Illinois 60611 -
dc.identifier.doi https://doi.org/10.4267/2042/66056


Files in this item

PDF 10-2015-HMGICID82.pdf 717.4Kb

This item appears in the following Collection(s)

Show simple item record





Advanced Search